At a glance
- Originator Abbott Laboratories
- Class Analgesics; Anti-inflammatories
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Pain
Most Recent Events
- 31 Dec 2012 Discontinued - Preclinical for Inflammation in USA (unspecified route) before 2012
- 31 Dec 2012 Discontinued - Preclinical for Pain in USA (unspecified route) before 2012
- 17 Jul 1998 Preclinical development for Inflammation in USA (Unknown route)